McMillan Office’s Biogen BIIB Stock Holding History

McMillan Office’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Hold	1,150	–	–	0.03%	169
2026 Q1	$211K	Hold	1,150	–	–	0.03%	177
2025 Q4	$202K	Buy	+1,150	New	+$188K	0.02%	178

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McMillan Office's BIIB Position: Q2 2026 in Review

McMillan Office held its Biogen (BIIB) position steady in Q2 2026 at 1,150 shares worth $248K. The position accounts for 0.03% of the portfolio, ranked #169.

McMillan Office first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

McMillan Office held 1,150 shares of Biogen worth $248K as of Q2 2026.
McMillan Office left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.03% of McMillan Office's portfolio in Q2 2026, its #169 holding.
McMillan Office first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.